The TabWrap news imo is extremely good. I had heard rumours that the tabwrap machine was installed in a ttp and that actually caused me some doubt and concern. This news is excellent.
From the Inyx website they have 210,000 sq ft of cgmp manufacturing in the UK and a 15,000 lab (between Ashton and Inyx Pharma). They are also a US company with the Puerto Rico site. My concern about the tabwrap system going to a ttp was what that meant for production, prioritisation, etc. With Inxy it is clear that this installation is part of bprg's global production capacity and plans for tabwrap. It also signals that essentially the technology is being kept in-house rather than handed out to the ttp - another very important point imo.
From a quick glance at the Inxy website they have substantial expertise scaling up production and supporting the commercialisation of novel/new dosage forms of products.
I have not had chance to look at the product launches or consider the tabwrap news further. However, we already know that 2 client products have successfully passed stability trials. Therefore I expect very rapid progress now that the machine is installed. My impression is that there are a substantial number of tabwrap developments underway and they will probably have been waiting on this machine installation before the later stages of scale-up and commercialisation. Also it is clear that the Dexo products have waited for stability testing in order to give priority to partner products.
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
